Secukinumab has demonstrated efficacy and safety in hard-to-treat anti–tumor necrosis factor α failure patients from the United Kingdom and Republic of Ireland: Results of the SIGNATURE study

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2018
This article has no abstract
Epistemonikos ID: 9549ce49a071f0e3cae012b5d17d1fe770ccabe7
First added on: Feb 15, 2022